原始来源记录
决策级顶线结果
Xilio Therapeutics 预计XTX501 1期数据将于2027年下半年公布
Xilio Therapeutics 已提供其 XTX501 项目的初步 Phase 1 数据预期时间表，该项目是一种双特异性 PD-1 / 掩蔽 IL-2 疗法。公司预计在 2027 年下半年报告该数据，前提是 FDA 批准其研究性新药 (IND) 申请，该申请目标于 2026 年年中提交。
关键事实
- 申报时间
- 2026年3月9日 12:00
- 事件
- 顶线结果
- 方向
- 积极
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 xlo-ex99_1.htm EX-99.1 Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ® This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to: development timelines and anticipated milestones for Xilio’s programs; the ultimate safety, efficacy, and potential benefits of any of Xilio’s current or future product candidates in any indication; any potential indications or commercial opportunities of our product candidates; the timing and receipt of future payments under Xilio’s collaboration or partnership agreements with AbbVie and Gilead; Xilio’s preliminary, unaudi